167 related articles for article (PubMed ID: 22984515)
1. Deficiency of the promyelocytic leukemia protein fosters hepatitis C-associated hepatocarcinogenesis in mice.
Herzer K; Carbow A; Sydor S; Sowa JP; Biesterfeld S; Hofmann TG; Galle PR; Gerken G; Canbay A
PLoS One; 2012; 7(9):e44474. PubMed ID: 22984515
[TBL] [Abstract][Full Text] [Related]
2. Promyelocytic leukemia protein deficiency leads to spontaneous formation of liver tumors in hepatitis C virus transgenic mice.
Straub K; Husen P; Baba HA; Trippler M; Wedemeyer H; Herzer K
Cancer Med; 2019 Jul; 8(8):3793-3802. PubMed ID: 31144474
[TBL] [Abstract][Full Text] [Related]
3. Hepatitis C virus core protein inhibits tumor suppressor protein promyelocytic leukemia function in human hepatoma cells.
Herzer K; Weyer S; Krammer PH; Galle PR; Hofmann TG
Cancer Res; 2005 Dec; 65(23):10830-7. PubMed ID: 16322229
[TBL] [Abstract][Full Text] [Related]
4. Promyelocytic leukaemia protein links DNA damage response and repair to hepatitis B virus-related hepatocarcinogenesis.
Chung YL; Wu ML
J Pathol; 2013 Aug; 230(4):377-87. PubMed ID: 23620081
[TBL] [Abstract][Full Text] [Related]
5. Hepatitis C-associated liver carcinogenesis: role of PML nuclear bodies.
Herzer K; Gerken G; Hofmann TG
World J Gastroenterol; 2014 Sep; 20(35):12367-71. PubMed ID: 25253937
[TBL] [Abstract][Full Text] [Related]
6. Promyelocytic leukemia protein induces arsenic trioxide resistance through regulation of aldehyde dehydrogenase 3 family member A1 in hepatocellular carcinoma.
Zhang X; Yang XR; Sun C; Hu B; Sun YF; Huang XW; Wang Z; He YF; Zeng HY; Qiu SJ; Cao Y; Fan J; Zhou J
Cancer Lett; 2015 Sep; 366(1):112-22. PubMed ID: 26118777
[TBL] [Abstract][Full Text] [Related]
7. Dual oncogenic and tumor suppressor roles of the promyelocytic leukemia gene in hepatocarcinogenesis associated with hepatitis B virus surface antigen.
Chung YL; Wu ML
Oncotarget; 2016 May; 7(19):28393-407. PubMed ID: 27058621
[TBL] [Abstract][Full Text] [Related]
8. Promyelocytic leukemia inhibits adipogenesis, and loss of promyelocytic leukemia results in fat accumulation in mice.
Kim MK; Yang S; Lee KH; Um JH; Liu M; Kang H; Park SJ; Chung JH
Am J Physiol Endocrinol Metab; 2011 Dec; 301(6):E1130-42. PubMed ID: 21846906
[TBL] [Abstract][Full Text] [Related]
9. PML tumor suppressor protein is required for HCV production.
Kuroki M; Ariumi Y; Hijikata M; Ikeda M; Dansako H; Wakita T; Shimotohno K; Kato N
Biochem Biophys Res Commun; 2013 Jan; 430(2):592-7. PubMed ID: 23219818
[TBL] [Abstract][Full Text] [Related]
10. Overexpression of promyelocytic leukemia protein and alteration of PML nuclear bodies in early stage of hepatocarcinogenesis.
Yoon GS; Yu E
J Korean Med Sci; 2001 Aug; 16(4):433-8. PubMed ID: 11511788
[TBL] [Abstract][Full Text] [Related]
11. IFN-alpha-induced apoptosis in hepatocellular carcinoma involves promyelocytic leukemia protein and TRAIL independently of p53.
Herzer K; Hofmann TG; Teufel A; Schimanski CC; Moehler M; Kanzler S; Schulze-Bergkamen H; Galle PR
Cancer Res; 2009 Feb; 69(3):855-62. PubMed ID: 19141642
[TBL] [Abstract][Full Text] [Related]
12. Arsenic trioxide and promyelocytic leukemia protein-adenovirus synergistically inhibit in vitro and in vivo growth of a hepatoma cell line.
Cui L; Zhang S; Zhang W; Hu Z; Cao Z; Li T
Oncol Res; 2010; 18(7):305-14. PubMed ID: 20377131
[TBL] [Abstract][Full Text] [Related]
13. Concordant expression of proto-oncogene promyelocytic leukemia and major histocompatibility antigen HLA class I in human hepatocellular carcinoma.
Xia M; Zhang JQ; Shen YQ; Xu LH; Chen AQ; Miao FQ; Xie W
Tissue Antigens; 2007 Oct; 70(4):272-82. PubMed ID: 17767548
[TBL] [Abstract][Full Text] [Related]
14. A CK2-dependent mechanism for degradation of the PML tumor suppressor.
Scaglioni PP; Yung TM; Cai LF; Erdjument-Bromage H; Kaufman AJ; Singh B; Teruya-Feldstein J; Tempst P; Pandolfi PP
Cell; 2006 Jul; 126(2):269-83. PubMed ID: 16873060
[TBL] [Abstract][Full Text] [Related]
15. The human promyelocytic leukemia protein is a tumor suppressor for murine skin carcinogenesis.
Virador VM; Flores-Obando RE; Berry A; Patel R; Zakhari J; Lo YC; Strain K; Anders J; Cataisson C; Hansen LA; Yuspa SH
Mol Carcinog; 2009 Jul; 48(7):599-609. PubMed ID: 19058256
[TBL] [Abstract][Full Text] [Related]
16. PML control of cytokine signaling.
Maarifi G; Chelbi-Alix MK; Nisole S
Cytokine Growth Factor Rev; 2014 Oct; 25(5):551-61. PubMed ID: 24861946
[TBL] [Abstract][Full Text] [Related]
17. Targeting promyelocytic leukemia protein: a means to regulating PML nuclear bodies.
Reineke EL; Kao HY
Int J Biol Sci; 2009 May; 5(4):366-76. PubMed ID: 19471587
[TBL] [Abstract][Full Text] [Related]
18. The promyelocytic leukemia protein stimulates SUMO conjugation in yeast.
Quimby BB; Yong-Gonzalez V; Anan T; Strunnikov AV; Dasso M
Oncogene; 2006 May; 25(21):2999-3005. PubMed ID: 16501610
[TBL] [Abstract][Full Text] [Related]
19. Promyelocytic leukemia protein-induced growth suppression and cell death in liver cancer cells.
Son SH; Yu E; Choi EK; Lee H; Choi J
Cancer Gene Ther; 2005 Jan; 12(1):1-11. PubMed ID: 15529177
[TBL] [Abstract][Full Text] [Related]
20. In vivo analysis of the role of aberrant histone deacetylase recruitment and RAR alpha blockade in the pathogenesis of acute promyelocytic leukemia.
Matsushita H; Scaglioni PP; Bhaumik M; Rego EM; Cai LF; Majid SM; Miyachi H; Kakizuka A; Miller WH; Pandolfi PP
J Exp Med; 2006 Apr; 203(4):821-8. PubMed ID: 16549595
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
